Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Catabasis Pharmaceuticals, Inc.    CATB

CATABASIS PHARMACEUTICALS, INC.

(CATB)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/01/2020 07/02/2020 07/06/2020 07/07/2020 07/08/2020 Date
6.41(c) 6.71(c) 6.67(c) 6.76(c) 6.7856 Last
155 459 180 666 251 952 142 596 27 655 Volume
-0.31% +4.68% -0.60% +1.35% +0.38% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -32,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -3,60x
Yield 2020 -
Sales 2021 6,75 M - -
Net income 2021 -28,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,38x
Yield 2021 -
Capitalization 121 M 121 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 17,9x
Nbr of Employees 27
Free-Float 99,9%
More Financials
Company
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics. The Company’s lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, in development for the treatment of Duchenne muscular dystrophy (DMD). In addition to... 
More about the company
Latest news on CATABASIS PHARMACEUTICALS,
06/30CATABASIS PHARMACEUTICALS : Joins Russell 3000 Index
AQ
06/29CATABASIS PHARMACEUTICALS :  Catabasis Joins Russell 3000® Index
BU
06/15CATABASIS PHARMACEUTICALS : Names Ben Harshbarger Senior Vice President, General..
AQ
06/12CATABASIS PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submi..
AQ
06/12CATABASIS PHARMACEUTICALS : Names Ben Harshbarger Senior Vice President, General..
BU
05/12CATABASIS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Co..
AQ
05/12CATABASIS PHARMACEUTICALS : Reports First Quarter 2020 Financial Results and Rev..
BU
05/12CATABASIS PHARMACEUTICALS : Presents Edasalonexent, a Potential Foundational The..
BU
04/28CATABASIS PHARMACEUTICALS : to Report First Quarter 2020 Financial Results on Tu..
BU
04/20CATABASIS PHARMACEUTICALS : to Present at 2020 Muscular Dystrophy Association Vi..
AQ
04/17CATABASIS PHARMACEUTICALS : to Present at 2020 Muscular Dystrophy Association Vi..
BU
03/25CATABASIS PHARMACEUTICALS : to Present at the Upcoming 2020 Solebury Trout Virtu..
BU
03/18CATABASIS PHARMACEUTICALS : to Present During the Muscular Dystrophy Association..
BU
03/10CATABASIS PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2019 Financial ..
BU
03/10CATABASIS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Co..
AQ
More news
News in other languages on CATABASIS PHARMACEUTICALS,
06/30CATABASIS PHARMACEUTICALS : Joins Russell 3000 Index
06/29CATABASIS PHARMACEUTICALS :  Catabasis Joins Russell 3000® Index
06/15CATABASIS PHARMACEUTICALS : Names Ben Harshbarger Senior Vice President, General..
06/12CATABASIS PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submi..
06/12CATABASIS PHARMACEUTICALS : Names Ben Harshbarger Senior Vice President, General..
More news
Chart CATABASIS PHARMACEUTICALS, INC.
Duration : Period :
Catabasis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATABASIS PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 37,50 $
Last Close Price 6,76 $
Spread / Highest target 788%
Spread / Average Target 455%
Spread / Lowest Target 122%
EPS Revisions
Managers
NameTitle
Jill C. Milne President, Chief Executive Officer & Director
Kenneth M. Bate Chairman
Noah Clauser Treasurer & Vice President-Finance
Joanne M. Donovan Chief Medical Officer & SVP-Clinical Development
Andrew Nichols Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CATABASIS PHARMACEUTICALS, INC.14.38%121
GILEAD SCIENCES, INC.17.61%95 859
VERTEX PHARMACEUTICALS36.59%77 539
REGENERON PHARMACEUTICALS70.68%65 084
WUXI APPTEC CO., LTD.45.47%31 379
GENMAB A/S53.43%22 516